Celcuity (NASDAQ: CELC) is one of 23 public companies in the “Medical laboratories” industry, but how does it weigh in compared to its rivals? We will compare Celcuity to similar companies based on the strength of its analyst recommendations, risk, institutional ownership, dividends, valuation, earnings and profitability.
Insider & Institutional Ownership
14.4% of Celcuity shares are held by institutional investors. Comparatively, 52.0% of shares of all “Medical laboratories” companies are held by institutional investors. 43.5% of Celcuity shares are held by insiders. Comparatively, 17.4% of shares of all “Medical laboratories” companies are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
This table compares Celcuity and its rivals gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Celcuity Competitors||$1.13 billion||$90.54 million||463.41|
Celcuity’s rivals have higher revenue and earnings than Celcuity. Celcuity is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
This table compares Celcuity and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a breakdown of recent ratings and price targets for Celcuity and its rivals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Celcuity currently has a consensus target price of $35.50, suggesting a potential upside of 31.97%. As a group, “Medical laboratories” companies have a potential upside of 3.53%. Given Celcuity’s stronger consensus rating and higher probable upside, research analysts plainly believe Celcuity is more favorable than its rivals.
Risk & Volatility
Celcuity has a beta of 0.21, meaning that its stock price is 79% less volatile than the S&P 500. Comparatively, Celcuity’s rivals have a beta of 1.37, meaning that their average stock price is 37% more volatile than the S&P 500.
Celcuity beats its rivals on 7 of the 13 factors compared.
Celcuity Inc., a cellular analysis company, discovers cancer sub-types and commercializes diagnostic tests to enhance the response rates of cancer patients treated with targeted therapies in the United States. The company is developing CELx tests to diagnose two new sub-types of HER2-negative breast cancer. It is also developing CELx tests to diagnose 14 new potential cancer sub-types in breast, lung, colon, ovarian, kidney, bladder, and hematological cancers. The company was founded in 2012 and is headquartered in Minneapolis, Minnesota.
Receive News & Ratings for Celcuity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celcuity and related companies with MarketBeat.com's FREE daily email newsletter.